MorphoSys Reports Promising Pre-clinical Data for MOR202
Combination Studies to be Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO)
23-May-2011 -
MorphoSys AG announced promising pre-clinical data on its proprietary drug candidate MOR202, a HuCAL-derived, fully human anti-CD38 antibody. Studies showed that by combining MOR202 with each of two approved drugs for the treatment of multiple myeloma, the anti-cancer activity of the antibody ...
antibodies
cancer
MorphoSys
+1